Therapeutic treatment of H. pylori associated gastroduodenal dis

Details Therapeutic treatment of H. pylori associated gastroduodenal dis Therapeutic treatment of H. pylori associated gastroduodenal dis

1995-08-18

1999-02-16

Housel, James C.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

4241941, 435 721, A61K 3902

Patent

active

058717498

DESCRIPTION:

BRIEF SUMMARY
This Application is a 371 of PCT/AU94/00416 filed Jul. 25, 1994, which claims foreign priority to Australian applications: PM3828, filed Feb. 14, 1994 and PMO157 filed Jul. 27, 1993.


FIELD OF THE INVENTION

This invention relates to the treatment of gastroduodenal disease associated with Helicobacter pylori infection and in particular it relates to the use of active immunisation as a treatment for H. pylori-associated gastroduodenal disease.


BACKGROUND OF THE INVENTION

The bacterium, Helicobacter pylori, is now well established as a major gastroduodenal pathogen, and more than 50% of the world population is infected with this organism which causes gastritis of varying severity. While no symptoms are apparent in a great proportion of infected persons, in a significant number of H. pylori infected persons overt disease may result. The majority (95%) of duodenal ulcers are associated with H. pylori infection; a causal role is shown by treatment studies which indicate that if the organisms can be eradicated at the time of ulcer healing then the ulcers do not recur--in contrast to 80% recurrence rate at one year in those who remain infected with the organisms. Furthermore, up to 80% of gastric ulcers are thought to be H. pylori associated (Blaser, 1992).
There is now increasing evidence of the harmful consequence of long term H. pylori infection. In countries such as China, Colombia and Japan the bacterium is picked up very early in life, and in these persons the gastritis slowly progresses until after 30-40 years of continual infection, severe gastric atrophy appears. Gastric atrophy is well documented as being the precursor lesion for gastric cancer, although the actual cancer that develops in an atrophied stomach is dependent on a myriad of other factors including diet. However, all the evidence to date would suggest that the cancer would not develop if it was possible to remove the H. pylori infection at an early age before the atrophy had developed (Parsonnet et al., 1991).
There is no laboratory animal model of H. pylori infection that can be used for large scale assessment of new anti-H. pylori therapies. However, a Helicobacter felis mouse model of gastric Helicobacter infection has been developed that has proved extremely useful in the screening of the potential of new antimicrobial therapeutic regimens. H. felis is a spiral shaped bacterium that is very closely related to H. pylori. This bacterium colonises the stomach of mice in a very similar way to H. pylori in the human, i.e. the main ecological niche is gastric mucus and the localisation of colonisation is antral dominant. In germfree mice, H. felis infection induces a gastritis that is very similar to the human H. pylori infection with a chronic inflammation accompanied by polymorphonuclear leucocyte infiltration. Infection with each organism results in the induction of a similar raised immune response against H. pylori and H. felis respectively (Lee et al., 1990).
The H. felis mouse model has proved to be very predictive of the efficacy of anti-H. pylori agents in humans. Thus, monotherapy with agents with high in vitro activity such as erythromycin show no significant in vivo effect against H. felis in mice, just as erythromycin has no anti-H. pylori effect in humans despite high antimicrobial effects in vitro. In contrast, the triple therapy regimens of a bismuth compound, metronidazole, and tetracycline or amoxycillin lead to a very high eradication rate in H. felis infected mice (Dick-Hegedus and Lee, 1991). Such triple therapies are the most successful human anti-H. pylori regimens, and at the present time are recommended as the first choice for anti-H. pylori therapy. However, established Helicobacter infections are difficult to treat, and current chemotherapeutic regimens remain suboptimal due to problems with efficacy, toxicity, drug resistance and reinfection (O'Connor, 1992).
Active immunisation of already infected patients has not been proven efficacious for any clinically manifest human infectious disease (Burke, 1992). Given t

REFERENCES:
patent: 5370872 (1994-12-01), Cryz et al.
patent: 5403924 (1995-04-01), Cover et al.
patent: 5459041 (1995-10-01), Blaser et al.
patent: 5538729 (1996-07-01), Czinn et al.
Czinn et al., Infection and Immunity, 59(7): 2359-2363 (1991).
Czinn et al., Vaccine 11(6): 637-642 (1993).
E. Dick-Hegedus et al., Scand J Gastroenterol 26: 909-915 (1991).
Goodwin et al., Helicobacter Pylori Biology and Clinical Practice, pp. 432-444 (1993).
Lee et al., Gastroenterology 99: 1315-1323 (1990).
O'Connor, Postgrad Med J 68: 549-557 (1992).
Parsonnet et al., The New England Journal of Medicine 325(16): 1127-1131 (1991).
Laszlo et al., Orvosi Hetilap 133: Evfolyam 6. Szam, pp. 359-361 (abstract).
Burke, Vaccine 11(8): 795-804 (1993).
Cox et al., Animal Parasite Control Ulitizing Biotechnology, pp. 49-112 (1992).
Blaser, Clinical Infectious Diseases 15: 386-393 (1992).
Czinn et al, Gastroenterology, vol. 100(Spt 2), A571, May, 1991.
McGhee, J.R. et al, Vaccine, vol. 10(2), 1992, pp. 75-88, 1992.
Clements, J.D. et al, Vaccine vol. 6(3), Jun. pp. 269-277, 1988.
Czinn et al, Infection & Immunity, vol. 59(7), 1991, pp., 2359-2363.
Rappuoli, R et al, Eur. J. Gastroenterol. & Hepatol, 1993, vol. 5 (Suppl 2), pp. 576-578.
Chen, et al (1993, Apr.), Gastroenterology, vol. 104(4), Apr., p(A681).
Genesis Report-DX, Jan. 1993, ISSN:1061-2289.
Chen. M et al (1994) FEMS Microbiology Letters, vol. 116, pp. 245-250.
HP Worldwide Quarterly, 1991-1992, pp. 1-7.
Heap, L. et al., Oct. 7-10, 1991, Microbiol. Ecol. Health Dis., vol. 4, pp. S229.
Dunkley, ML. et al, Microb. Ecol. Health Dis. vol. 4 (Spec. Issue), 1991, p. S148.
Davin, C. et al, Gasteroenterology, vol. 104(4), Apr. 1993, PA1668.
Laszlo, V. et al 1992, vol. 133(6), pp. 359-361, Orvosi Hetilap.
Pavlovskis, OR et al, American Soc. Microbiol, 1991, May 5-9, 1991, p. 119, #E11.
Lee, CK et al, J of Infect. Disease, 1995, vol. 172, pp. 161-172.

Affiliated with

Also associated with

Rating

Therapeutic treatment of H. pylori associated gastroduodenal dis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic treatment of H. pylori associated gastroduodenal dis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic treatment of H. pylori associated gastroduodenal dis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2059735